Literature DB >> 22309083

Inflammatory mechanisms and oxidative stress in Peyronie's disease: therapeutic "rationale" and related emerging treatment strategies.

Gianni Paulis1, Tommaso Brancato.   

Abstract

Peyronie's disease (PD) is a connective tissue disorder characterized by a fibrous plaque involving the tunica albuginea of the penis. The inelastic fibrous plaque leads to a penile curvature. Several Authors have suggested an immunological genesis of this disease, others have linked PD with Dupuytren's contracture. Signs of this disease are curvature, penile pain, penile deformity, difficulty with coitus, shortening, hinging, narrowing and erectile dysfunction. The natural history of PD and the clinical course can develop from spontaneous resolution of symptoms to progressive penile deformity and impotence. Surgical treatment is indicated when patients fail the conservative medical treatment and however, only in case of disease stabilization with a condition of impossibility of penetration. The medical treatment is indicated in the development stage of PD for at least one year after diagnosis and whenever in case of penile pain. Current non-surgical therapy includes vitamin-E, verapamil, para-aminobenzoate, propoleum, colchicine, carnitine, tamoxifen, interferons, collagenase, hyaluronidase, cortisone, pentoxifylline, superoxide dismutase, iontophoresis, radiation, extracorporeal shock wave therapy (ESWT) and the penile extender. The etiology of this fibrotic disease is not widely known, although in recent years pathophysiological knowledge has evolved and new studies propose the penile trauma as cause of the disease. The penile trauma results in a delamination of the tunica albuginea with a consequent small hematoma, then the process evolves as an inflammation with accumulation of inflammatory cells and production of reactive oxygen species (ROS). In the course of the inflammation, Peyronie's disease occurs due to the activation of nuclear factor kappa-B, that induces the production of inducible nitric oxide synthase (iNOS), with an increase of nitric oxide, leading to increased production of peroxynitrite anion. All these processes result in the proliferation of fibroblasts and myo-fibroblasts and excessive production of collagen between the layers of the tunica albuginea (penile plaque). Referring to the current knowledge of inflammatory and oxidative mechanisms of PD, a possible therapeutic strategy is then analyzed.
© 2012 Bentham Science Publishers

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22309083     DOI: 10.2174/187152812798889321

Source DB:  PubMed          Journal:  Inflamm Allergy Drug Targets        ISSN: 1871-5281


  14 in total

Review 1.  Contemporary Review of Peyronie's Disease Treatment.

Authors:  Edward Capoccia; Laurence A Levine
Journal:  Curr Urol Rep       Date:  2018-05-17       Impact factor: 3.092

Review 2.  Update on medical management of Peyronie's disease.

Authors:  Ronny B W Tan; Premsant Sangkum; Gregory C Mitchell; Wayne J G Hellstrom
Journal:  Curr Urol Rep       Date:  2014-06       Impact factor: 3.092

Review 3.  Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence.

Authors:  Elizabeth J Traore; William Wang; Faysal A Yafi; Wayne J G Hellstrom
Journal:  Ther Adv Urol       Date:  2016-03-22

4.  The contribution of the immune system to genitourinary fibrosis.

Authors:  Karen M Doersch; Daniel Barnett; Abbie Chase; Daniel Johnston; J Scott Gabrielsen
Journal:  Exp Biol Med (Maywood)       Date:  2022-05-07

5.  Intralesional hyaluronic acid: an innovative treatment for Peyronie's disease.

Authors:  Romano Gennaro; Davide Barletta; Gianni Paulis
Journal:  Int Urol Nephrol       Date:  2015-08-11       Impact factor: 2.370

6.  Antioxidant Mechanism of Xiaojin Pill () for Treatment of Peyronie's Disease in Rats Based on Matrix Metalloproteinases.

Authors:  Qiang Geng; Fu Wang; Qiang Han; Shao-Feng Chen; Bin Ouyang; Zhong Li; Yu Zhao; Qing-He Gao; Guo-Jin Yu; Jun Guo
Journal:  Chin J Integr Med       Date:  2019-10-24       Impact factor: 1.978

7.  Clinical and epidemiological characteristics of young patients with Peyronie's disease: a retrospective study.

Authors:  Gianni Paulis; Giorgio Cavallini; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Andrea Fabiani
Journal:  Res Rep Urol       Date:  2015-07-09

8.  Con: does shockwave therapy have a place in the treatment of Peyronie's disease?

Authors:  Abdullah Alkhayal; Serge Carrier
Journal:  Transl Androl Urol       Date:  2016-06

9.  Stromal Vascular Fraction Combined with Shock Wave for the Treatment of Peyronie's Disease.

Authors:  Elliot B Lander; Mark H Berman; Jackie R See
Journal:  Plast Reconstr Surg Glob Open       Date:  2016-03-02

10.  Efficacy and safety evaluation of pentoxifylline associated with other antioxidants in medical treatment of Peyronie's disease: a case-control study.

Authors:  Gianni Paulis; Davide Barletta; Paolo Turchi; Antonio Vitarelli; Giuseppe Dachille; Andrea Fabiani; Romano Gennaro
Journal:  Res Rep Urol       Date:  2015-12-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.